Post by Towards Healthcare Research & Consulting

Johnson & Johnson Medicine Pipeline Tracking (2026) Johnson & Johnson isn't just launching new medicines, it's building one of the strongest pharmaceutical pipelines in the industry. The company is currently tracking 90+ clinical and regulatory programs across oncology, immunology, neuroscience, cardiovascular diseases, pulmonary hypertension, and rare diseases. In 2025, Johnson & Johnson reported USD 94.2 billion in total revenue. Its Innovative Medicine business alone generated USD 60.4 billion, contributing nearly 64% of the company's overall sales. To keep future growth on track, the company invested more than USD 17 billion in research and development during 2025. That investment is supporting dozens of Phase I, II, and III clinical trials, along with multiple regulatory submissions worldwide. #Oncology continues to be the biggest focus area. #DARZALEX remained the company's best-selling medicine, generating approximately USD 14.4 billion in 2025, with 23% year-over-year growth, while new studies continue to expand its use into earlier treatment lines. The company is also scaling #CARVYKTI, its CAR-T therapy for multiple myeloma, by expanding manufacturing and evaluating the therapy in earlier-stage patients. In lung cancer, #RYBREVANT and #LAZCLUZE are advancing through multiple Phase III trials, strengthening Johnson & Johnson's long-term oncology portfolio. In immunology, #TREMFYA delivered approximately USD 5.2 billion in 2025 sales, growing by more than 40% year over year. At the same time, #STELARA sales declined to around USD 6.1 billion, falling by over 40% as biosimilar competition entered the market. This clearly shows how Johnson & Johnson is replacing mature blockbuster medicines with next-generation therapies that have larger long-term growth potential. Overall, the numbers tell the story. USD 94.2B in total revenue, USD 60.4B from Innovative Medicine, USD 17B+ invested in R&D, and 90+ active pipeline programs demonstrate that Johnson & Johnson is not only managing today's portfolio but actively building the next generation of blockbuster medicines. Looking for answers to your specific business questions? Our experts provide FREE customized sample reports: https://lnkd.in/gzQGx5TT #JohnsonandJohnson #Pharma #LifeScience #PharmaPipeline #PharmaMedicine